Abstract. In B-cell chronic lymphocytic leukemia (CLL), Rai stage, immunoglobulin gene mutational status, chromosomal abnormalities, CD38 and ZAP-70 expression were used as prognostic markers. In this study, to understand the molecular basis of chromosomal abnormalities leading to tumor progression, 90 CLL patients were grouped into poor prognosis (with 11q deletion and trisomy 12) and good prognosis (with normal karyotype and 13q deletion) and their clinical outcome was assessed. Gene expression profiles of 35 CLL samples with poor outcome (11q deletion, n=9; trisomy 12, n=5) and good outcome (13q deletion, n=13; normal karyotype, n=8) were analyzed using oligonucleotide microarray. Significance analysis of microarray (SAM) identified 27 differentially expressed genes between these two subgroups with significant overexpression of ATF5 and underexpression of CDC16, PCDH8, SLAM, MNDA and ATF2 in CLL patients with poor outcome. ATF5 gene expression in CLL was further studied because of its role in the regulation of cell cycle progression/differentiation and apoptosis. The overexpression of ATF5 was confirmed by real-time PCR using 39 CLL samples from the poor and good outcome groups. ATF5 was significantly (p<0.001) overexpressed in the poor outcome group. Furthermore, ATF5 expression was significantly higher in the 11q deletion as well as trisomy 12 group alone compared to the 13q deletion and normal karyotype groups. ATF5 overexpression was also associated with significantly (p=0.04) shorter time to treatment. Similarly, expression of five underexpressed genes also correlated with longer time to treatment. Thus, this report demonstrates that ATF5 may be one of the key genes involved in increased proliferation and survival in 11q deletion or trisomy 12, whereas CD16, CD86, SLAM, MNDA and ATF2 may be involved in the decreased proliferation of CLL cells with 13q deletion or normal karyotype.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by a highly variable clinical course. Some patients have an aggressive disease and they succumb within a short period after diagnosis, whereas others exhibit a more stable and indolent disease and survive for a prolonged period without any need of therapy (1, 2) . To predict prognosis and to decide the treatment strategy after the diagnosis, prognostic factors are of immense importance (3) . Based on tumor cell burden, two major clinical staging systems were developed by Rai et al (4) and Binet et al (5) . Although these staging systems are useful, their ability to predict outcome, particularly in early stages of the disease, is limited (6) . Therefore, prognostic markers related to the biology of CLL, such as chromosomal abnormalities and immunoglobulin variable heavy chain (IgV H ) mutation status, are increasingly being evaluated for their prognostic value (7). Damle et al (8) and Hamblin et al (9) correlated the presence and absence of mutated IgV H with a favorable and an unfavorable clinical course, respectively. At present, IgV H mutation status is considered as one of the most reliable prognostic markers (6, 7) . However, this analysis requires technically skilled DNA sequencing, which is also not commonly available for routine clinical practices. Thus, easily determined prognostic markers are required. In addition, to understand the molecular basis of prognostic markers, such as in the case of cytogenetic abnormalities, CD38 and ZAP-70 expression may help identify genes to develop therapeutic strategies.
Chromosomal abnormalities are seen in ~80% of CLL cases by fluorescence in situ hybridization (FISH) (10) . We (11, 12) and others (10) have shown that CLL cases with 11q deletion, 17p deletion and trisomy 12 have a more aggressive disease compared to CLL with 13q deletion or normal karyotype. Krober et al (13) have shown that the frequency of occurrence of genomic aberrations was equal in the mutated and unmutated V H subgroups, but chromosomal abnormalities associated with poor prognosis, such as 11q deletion and 17p deletion, were almost exclusively found in the IgV H unmutated subgroup, whereas favorable abnormalities such as 13q deletion were associated with IgV H CLL-mutated subgroups. Though genomic abnormalities are of independent prognostic value in multivariant analysis, little is known about the underlying genetic and molecular mechanisms responsible for aggressive or indolent clinical behavior of CLL patients. Therefore, in the present study CLL patients were divided into two groups, one with the 11q deletion and trisomy 12 as the poor outcome group and another with the 13q deletion and a normal karyotype as the good outcome group. We determined the differential gene expression between these two subgroups, and identified differentially expressed genes were confirmed using real-time PCR and/or correlated with time to treatment as a measure of disease progression. Thus, these results provide a molecular basis of chromosome abnormalities in CLL patients.
Materials and methods
Patients. In this study, CLL patients without treatment or patients who were not treated for the prior 6 months were included. All patients were diagnosed with CLL based on clinical and laboratory evaluations. Peripheral blood samples were collected from 90 different CLL patients with informed consent using an Institutional Review Board (IRB) approved protocol. To determine the molecular basis of chromosomal abnormalities on tumor progression in CLL, cytogenetic analysis was performed on 90 patients using FISH. The distribution of chromosomal abnormalities in these patients was as follows: 11q deletion (n=13, 14.4%), trisomy 12 (n=17, 18.8%), 13q deletion (n=28, 31.1%), 17p deletion (n=6, 6.6%), and normal karyotype (n=26, 28.8%). The other patient information, such as age, gender, status of other prognostic markers, clinical stage and time to treatment, were obtained and used for the determination of clinical characteristics and outcome.
Isolation and characterization of CLL cells. Mononuclear cells (MNCs) were isolated from heparinized whole blood from CLL patients using Accu-Prep™ lymphocyte separation medium by Ficoll-Hypaque density centrifugation method (Accurate Chemical and Scientific Corp., Westbury, NY, USA) as described previously (11, 14) . The immunophenotypes of the isolated MNCs were determined by flow cytometry with flurochrome (phycoerythrin/PE or fluoroscein isothiocyanate/FITC)-labeled antibodies specific for cell surface markers (11) . The cells were stained using the following flurochrome-conjugated antibodies: CD3-FITC, CD5-PE, CD19-PE, CD38-PE (BD Pharmingen, San Jose, CA, USA) and a combination of conjugated antibodies: CD3-FITC and CD38-PE; CD5-PE and CD19-FITC; CD19-FITC and CD38-PE (12) (12) . The purity of RNA was determined by 1% Trisacetate-EDTA (TAE) agarose gel electrophoresis and quantitation was performed by spectrophotometry. The CLL RNAs were used for gene expression profiling using DNA microarray chip (MWG Biotech, Germany, Human 10K oligo set A) consisting of 50-mer oligonucleotide representing 10,000 different genes. The RNA from CLL samples and Stratagene™ reference mRNA were reverse transcribed, then labeled with Cy3 or Cy5 fluorescence dyes and hybridized with array chip as described earlier (11, 12) . The hybridized microarray slides were scanned and images were collected by using an Axon 4000B scanner (Axon Instruments, Union City, CA, USA). The ratios of fluorescence intensity for each spot/gene/element were obtained by using GenePix 6.0 software. All data files were collated and analyzed using BRB analysis tools.
Quantitative real-time PCR for ATF5. Expression levels of RNA transcripts were determined by real-time PCR using gene-specific primers as provided in Table I . cDNA was prepared from 5 μg of total RNA from each CLL sample (11) . Complementary DNAs were mixed with primers and FastStart SYBR-Green Master mix (Roche, Indianapolis, IN, USA), and real-time PCR was performed using the MyiQ™ Table I . List of primers used in real-time PCR analysis.
Single-Color real-time PCR detection system (Bio-Rad, Hercules, CA, USA). PCR conditions used were 30 sec at 95˚C, 45 sec each at 60˚C and at 72˚C. HPRT, a housekeeping gene, was used as a control.
Statistical analyses. CLL patients were grouped on the basis of chromosomal abnormalities. The time period from diagnosis to the first treatment was used as a parameter of disease progression or clinical outcome in CLL patients in the present study. The Kaplan-Meier method was used to determine the distribution of time to treatment among grouped patients. The log rank test was also used to assess the relationship between groups of different chromosomal abnormalities with time to treatment. Relative gene expression levels obtained from real-time PCR were used as a measure of expression of ATF5. The mean expression levels of ATF5 for each sample were arranged and then divided into groups by their median value. The log rank test was performed to compare the time to treatment between the above and below median groups. Similar statistical analyses were performed to determine the relationship between expression of CD16, PCDH8, SLAM, MNDA and ATF2 by comparing their transcription levels obtained from DNA microarray data to time to treatment. A p-value ≤0.05 was considered statistically significant.
Results
Clinical evaluation. CLL patients with different chromosomal abnormalities were analyzed using different clinical parameters and the status of other prognostic markers. There was no statistically significant correlation between the age of the patients and the specific chromosomal abnormality subgroups. There was the indication of an (p=0.067) association between gender and type of chromosomal abnormality where more male patients (66.7%) had poor outcome chromosome abnormalities than female patients (33.3%) (Table II) . There was a significant association between CD38 expression in CLL cells and poor outcome chromosomal abnormality Table II . Patient characteristics. Cytogenetic abnormality data in 90 CLL patients were used to determine the relationship between the cytogenetic abnormality and disease progression as measured by time to treatment using the log rank test. CLL patient subgroups with 11q deletion, trisomy 12 and 17p deletion were associated with significantly shorter time to treatment compared with CLL patients with 13q deletion and normal karyotype. (Panel B) CLL patients with 11q deletion and trisomy 12 cytogenetic abnormalities together and 13q deletion and normal karyotype cytogenetic abnormalities together were correlated with clinical outcome as measured by time to treatment using the log rank test. The poor outcome group was associated with significantly (p=0.003) shorter time to treatment compared with CLL patients from the good outcome group.
(p=0.008), as well as between the presence of high levels of ß-2 microglobulin in blood serum and poor outcome chromosomal abnormality, (p=0.039). In both of these cases, higher expression levels were associated with the poor outcome chromosomal abnormality group. CLL patients with 11q deletion and trisomy 12 poor outcome chromosome abnormalities were associated with unmutated IgV H and presence of bulky lymphadenopathy (Table II) .
Cytogenetic analysis. Peripheral blood samples from ninety CLL patients were screened for known chromosomal abnormalities by FISH. The incidences/frequencies of each chromosomal abnormality were: 11q deletion (n=13) 14.4%, trisomy 12 (n=17) 18.8%, 13q deletion (n=28) 31.1%, 17p deletion (n=6) 6.6%, and abnormalities and normal karyotype (n=26) 28.8%; which were consistent with the large studies performed earlier on CLL with chromosomal abnormalities (10, 11, 16, 17) . In addition, as reported by our laboratory and others (10, 16, 17) , CLL patients with 11q deletion, trisomy 12 and 17p deletion were associated with a progressive disease. Furthermore, this report included about twice the number of patients compared to our earlier report. There was a significant association (p=0.01) between time to treatment and type of chromosomal abnormality (Fig. 1A) . The 11q deletion and trisomy 12 patients were associated with shorter time to treatment (for 11q deletion, 11 months; for trisomy 12, 25 months) compared to 13q deletion and normal karyotype patients (for 13q deletion, 48 months; for normal karyotype, 60 months) at a 95% confidence level. Notably, unlike other reports, the 17p deletion chromosomal abnormality showed a similar pattern as trisomy 12.
In the present study, to analyze the biological and clinical parameters among different abnormality groups, we used a mixed approach for hierarchical grouping for chromosomal abnormalities described by Dohner et al (10) and by us (11). In general, CLL patients with two or more chromosomal abnormalities are associated with poor outcome. We categorized the samples with both poor outcome chromosomal abnormalities (11q deletion or trisomy 12) and good outcome chromosomal abnormalities (13q deletion or normal karyotype). It is known that each chromosomal abnormality has independent prognostic value, and excluding one type of chromosomal abnormality will not affect the grouping of other abnormalities. The 11q deletion group, which had 11q deletions but not trisomy 12, and the trisomy 12 group, which had trisomy 12 but not 11q deletions, were grouped together under the poor outcome group. The 13q deletion group, which contained neither 11q deletion nor trisomy 12, and the normal karyotype group, where no chromosomal abnormality was detected were grouped together into the good outcome chromosomal abnormality group. When we analyzed these two groups together for clinical outcome, the poor outcome group had significantly (p=0.003) shorter time to treatment (12 months) compared to the good outcome group (60 months) (Fig. 1B) . Thus these analyses confirmed the validity of our poor and good clinical outcome CLL subgroups. Subsequent analyses were based on these two groups.
Differential gene expression in cytogenetic abnormality CLL subgroups. CLL cells isolated from the poor outcome and the good outcome chromosomal abnormality CLL subgroups were analyzed for their gene expression pattern using oligonucleotide microarray technique. Significance analysis of microarray (SAM) was used to identify the differentially expressed genes. At the 99% and 95% confidence levels the number of differentially expressed genes between these two groups, were 4 and 7 respectively. At the low confidence level (70%) two other genes (hypothetical protein flj22357 similar to epidermal growth factor and hypothetical protein flj12973) including ATF5 were overexpressed. In all these cases, ATF5 was the most significantly overexpressed gene in the poor outcome CLL subgroup. ATF5 is a transcription factor involved in cell cycle regulation, cellular differentiation and apoptosis. Furthermore, when the analysis was performed at the 90% confidence level, the SAM analyses identified 27 consistently differentially expressed genes as detailed in Table III . Fig. 2 demonstrates a supervised cluster diagram showing expression levels of these 27 genes in red and green color. Among these genes, ATF5 was significantly (p=0.024) overexpressed in the poor prognosis chromosomal abnorm-ality subgroup compared to the good outcome subgroup; whereas CDC16, SLAM, MNDA, ATF-2 and PCDH8 were underexpressed in the poor outcome cytogenetic abnormality CLL subgroup. Although there were other genes that were underexpressed in the poor outcome CLL subgroups, only the genes involved in cell cycle regulation, proliferation and immune response were included in further analyses.
Confirmation of overexpression of ATF5 in the poor outcome CLL subgroup.
Since the SAM analyses identified ATF5 as one of the most significantly overexpressed genes in the poor outcome CLL subgroups, the overexpression was confirmed by real-time PCR. Fig. 3 shows the results of these expression value analyses. Fig. 3A shows the transcript levels from the microarray analyses from 35 different patient samples. There was a significant overexpression of ATF5 in the poor outcome chromosomal abnormality CLL subgroup compared to the good outcome chromosomal abnormality CLL subgroup. Since ATF5 is a key gene in the regulation of cell cycle and apoptosis, before embarking on in-depth studies on the role of ATF5 in CLL proliferation and survival, we elected to further confirm the ATF5 expression using real-time PCR analyses. Fig. 3B shows the results of real-time PCR demonstrating the relative expression levels of ATF5 in the poor outcome chromosomal abnormality CLL subgroup as measured by Ct values compared to the good outcome CLL subgroup. Thus the real-time PCR analyses confirmed the overexpression of ATF5 corresponding to an aggressive disease. Fig. 4 shows a linear relationship between the expression levels of ATF5 in the CLL cells from different chromosomal abnormality subgroups in this study as determined by real-time PCR. These results demonstrated that ATF5 expression was highest in 11q deletion patients, second highest in trisomy 12 patients, third highest in 13q deletion patients and lowest in normal karyotype patients.
Correlation of ATF5 expression and time to treatment.
Kaplan-Meier analysis was performed to determine whether Table III . Differentially expressed genes between poor and good prognosis chromosomal abnormality groups. ------------------------------------------------------------------------------------------------------------------------------- ATF5 expression was related to clinical outcome in CLL patients. In this analysis, ATF5 expression levels as measured by real-time PCR in different chromosomal abnormality CLL subgroups were correlated with time to first treatment using the log rank test. Fig. 5 demonstrates that CLL patients with high ATF5 expression had significantly shorter time to treatment (p=0.04) compared to CLL patients with low ATF5 expression. More specifically, CLL patients with high ATF5 expression had 16 months to first treatment compared to CLL patients with low ATF5 expression who had 60 months to first treatment.
-------------------------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------------------
Correlation of MNDA, ATF2, SLAM, CDC16 and PCDH8
with time to treatment. Genes such as MNDA, ATF2, SLAM, CDC16 and PCDH8 were underexpressed in the poor outcome chromosomal abnormality CLL group. In other words, these genes were overexpressed in the good outcome chromosomal abnormality CLL subgroup. In order to further elucidate the role of these genes in CLL cell biology and/or clinical behaviors, the expression levels of these genes were correlated with time to treatment in these CLL patients using the log rank test. Fig. 6 shows the results of these analyses. There was a significant correlation between the expression of MNDA, ATF2, SLAM, CDC16 and PCDH8 with time to treatment. The higher expression of MNDA was significantly associated with longer time to treatment (74 months) compared to CLL patients with low MNDA expression (24 months). Similarly, lower and higher expression of other genes was correlated with time to treatment: for ATF2, 22 vs 72 months; for SLAM, 24 vs 60 months; for CDC16, 20 vs 60 months and for PCDH8, 24 vs 60 months.
Discussion
This report describes the gene expression profiles associated with different chromosomal abnormality CLL subgroups.
Cytogenetic analysis using FISH detected chromosomal abnormalities in ~80% of CLL cases and the remaining 20% were of normal karyotype (10, (16) (17) (18) . We and others have shown that chromosomal abnormalities influence the survival and progression of disease and, more specifically, 11q deletion, trisomy 12 and 17p deletion are associated with a more aggressive clinical outcome compared to 13q deletion and normal karyotype CLL subgroups. In previous studies (11, 12) we have shown that time to therapy was an endpoint to measure clinical progression in CLL patients. In accordance with previous studies (10, 11) , our present study has shown that the 11q deletion and trisomy 12 group had the shortest time to treatment compared to the 13q deletion and normal karyotype CLL subgroups. Interestingly, disease progression in patients with 17p deletion fluctuated between trisomy 12 and 13q deletion. This could have been due to the small sample size, and it was hard to reach a conclusion. Though it is well established that 11q deletion, trisomy 12 and 17p deletion in CLL indicate poor prognostic values, the underlying molecular mechanism is still unknown. To follow Figure 5 . Association of ATF5 overexpression with disease progression. ATF5 expression levels were correlated with disease progression as determined by time to treatment. CLL patients with high expression of ATF5 had a significantly shorter time to treatment (p=0.04). Figure 6 . Association of underexpression of CD16, PCDH8, SLAM, MNDA and ATF2 with disease progression. The levels of transcripts for the underexpressed 5 genes were correlated with time to treatment using the log rank test. Underexpression of these genes was associated with significantly shorter time to treatment: MNDA, p=0.023; CDC16, p=0.024; SLAM, p=0.035; ATF2, p=0.001; and PCDH8, p=0.045. up on our previous finding of a unique gene expression pattern in 11q deletion abnormality (11) , in the present study we addressed the issue of differentially expressed key genes associated with poor prognostic chromosomal abnormality CLL patients with 11q deletion and trisomy 12.
The gene expression profiles were compared between the poor outcome and the good outcome groups using oligonucleotide DNA microarray, and the SAM analyses revealed the differentially expressed genes ATF5, CDC16, PCDH8, SLAM, MNDA and ATF2. ATF5 was the most highly overexpressed gene in the poor outcome group. ATF5, also known as ATFx or ATF7, is a member of the activating transcriptional factor or cAMP response element-binding (ATF/CREB) family of basic leucine zipper (bZIP) protein (19, 20) . Its role has been shown to regulate the differentiation process (19) and to inhibit apoptosis (21) . Both differentiation and apoptosis play a major role in the cellular development cycle. Failure in one of these physiological processes may lead to cancer, where a cell either regains its ability to reenter the cell cycle and proliferate or escapes from natural death and begins accumulating in the body (21) . Therefore, factors affecting these processes are very critical in cancer biology, and ATF5 is one of the factors which affects both processes. ATF5 overexpression has also been shown in malignant CLL cells compared to normal B-cells when activated with CD40 ligand (22) . As it is well known that many cellular processes such as cell cycle, gene expression, protein synthesis and cellular transport are regulated through phosphorylation, ATF5 has also been identified as a factor which physically interacts with protein-tyrosine phosphatase (PTPase) (20) .
We showed that overexpression of ATF5 was significantly associated with poor (11q deletion and trisomy 12) chromosomal abnormality CLL subgroups. CLL subgroups with 11q deletion were associated with the poorest outcome and had a significantly higher level of expression of ATF5 than the other chromosomal abnormality CLL subgroups. Trisomy 12 was second in predicting a grave outcome with second shortest time to treatment and second highest overexpression of ATF5. Our results not only confirmed the report of overexpression of the ATF5 gene in malignant CLL cells (22) but also demonstrated that relative expression of ATF5 was highly correlated with degree of malignancy, disease progression and outcome of patients. In addition, there was a linear relationship between the level of ATF5 expression and severity of the disease in CLL. Thus, our report is the first to show that higher ATF5 mRNA expression may be a marker of the aggressiveness of the peripheral blood CLL cells.
The majority of the underexpressed genes were related with nucleic acid replication, transcription, repair and metabolism (RPA3, POLG2, M6A, TDPGD, MNDA, ATF2, DCK), which indicated a tendency towards an insufficiency of functions to maintain the integrity of the genome in the poor outcome chromosomal abnormality group compared to the good outcome chromosomal abnormality group. In addition, genes related with immune response and cell adhesion or signaling or activation such as CDC16, CD86 antigen, SLAM, PCDH8, PIASX-ß, MNDA, SNX3 were also underexpressed, which showed poor immunity and lymphocyte trafficking in the poor prognosis group. These results agree with the finding that decreased expression of genes related to cellular adhesion indicates low patient survival (23) or poor outcome. Moreover, ATF2 was underexpressed in the poor outcome chromosomal abnormality group. Interestingly, ATF2 is involved in multiple intracellular signal transduction pathways and is considered a candidate tumor suppressor gene, which plays a role in the development of human lung cancer, neuroblastoma and breast cancer (24) .
In summary, these results identify the differentially expressed genes and demonstrate an association of overexpression of the ATF5 gene and underexpression of MNDA, ATF2, SLAM, CDC16 and PCDH8 with poor outcome chromosomal abnormality CLL patients. ATF5 may be one of the key genes responsible for inducing cell proliferation in CLL patients with 11q deletion and trisomy 12 chromosomal abnormalities, while other genes such as MNDA, ATF2, SLAM, CDC16 and PCDH8 may inhibit cell proliferation in CLL patients with 13q deletion and normal karyotype. Furthermore, these results open new avenues to further explore the details of the mechanisms of cytogenetic abnormality-induced disease progression.
